세계의 COVID 19 최신 치료제 시장 보고서(2024년)

COVID-19 Current Therapy Global Market Report 2024

US $ 5,000 ￦ 7,219,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,500 ￦ 10,828,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,438,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

COVID 19 최신 치료제 시장 규모는 향후 몇 년동안 급격히 감소할 것으로 예상됩니다. 2025년에는 연평균 복합 성장률(CAGR) -60.1%로 23억 4,000만 달러까지 감소할 것으로 예상됩니다. 예측 기간의 감소는 세계 백신 출시의 영향, 장기적인 영향과 만성 질환, 규제 및 시장 접근성 문제, 세계 경제 요인에 기인한 것으로 보입니다. 예측 기간 동안 주요 동향으로는 단클론 항체 치료제, 회복기 혈장 치료제, 세포 기반 치료제, 항바이러스 치료제 개발에 대한 투자, 정부 기관과의 협력, 다른 제약사와의 전략적 제휴 등이 있습니다.

신종 코로나바이러스 감염증(코로나19)의 대유행은 COVID 19 최신 치료제 시장의 성장에 크게 기여했습니다. 세계보건기구(WHO)는 이번 사태를 세계적 대유행으로 선언했으며, 2022년 8월 기준 전 세계 코로나19 감염자 수는 5억 8,180만 명에 달했습니다. 신종 코로나바이러스 감염증(코로나19)에 대해 공식적으로 승인된 약물이 없기 때문에 코로나 치료에 사용되는 재사용 약품에 대한 수요가 큽니다. 전 세계 국가들이 의약품 부족에 시달리고 있으며, 제조업체들은 급증하는 세계 수요에 대응하기 위해 생산을 확대해야 하는 상황입니다. FDA가 시작한 코로나19 감염병 치료 가속화 프로그램(CTAP)은 잠재적인 새로운 코로나19 치료제의 개발을 촉진하고 환자에게 신속하게 제공할 수 있도록 설계된 특별 긴급 프로그램입니다.

COVID 19 최신 치료제 시장의 예상 성장은 의료 인프라의 확장으로 인해 촉진되고 있습니다. 의료 산업은 환자의 치료, 예방, 재활, 재활 및 완화 치료를 제공하는 제품과 서비스를 제공하는 부문을 통합하는 데 중요한 역할을 하고 있습니다. 강력한 의료 인프라는 코로나19 치료를 효과적으로 수행하고, 적시에 환자 치료를 보장하고, 연구 및 임상시험을 지원하고, 최적의 치료를 제공하는 데 필수적인 자원을 제공하는 데 필수적입니다. 실례로, 2023년 5월 미국 의료협회는 미국의 병원 수가 2022년 6,093개에서 6,129개로 증가했다고 보고했습니다. 또한 영국 통계청의 보고서에 따르면 2020년부터 2021년까지 영국의 의료비 지출은 명목상 9.4%, 실질적으로는 9.7% 증가했다고 밝혔습니다. 따라서 의료 산업의 확대는 신종 코로나바이러스 감염증(코로나19) 최신 치료 시장의 성장을 이끄는 주요 원동력입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

• 고인플레이션이 시장에 미치는 영향
• 우크라이나·러시아 전쟁이 시장에 미치는 영향
• 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

• 세계의 COVID 19 최신 치료제 시장 성장 촉진요인과 억제요인
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
• 세계의 COVID 19 최신 치료제 시장 규모 실적과 성장률, 2020-2023년
• 세계의 COVID 19 최신 치료제 시장 규모와 성장 예측, 2023-2024년, 2025년

제6장 시장 세분화

• 세계의 COVID 19 최신 치료제 시장, 약제 유형별 세분화, 실적과 예측, 2020-2023년, 2023-2024년, 2025년
• Remdesivir
• Hydroxychloroquine
• Ritonavir
• Lopinavir
• Interferon Beta
• 기타
• 세계의 COVID 19 최신 치료제 시장, 투여 경로별 세분화, 실적과 예측, 2020-2023년, 2023-2024년, 2025년
• 경구
• 정맥내
• 세계의 COVID 19 최신 치료제 시장, 최종사용자별 세분화, 실적과 예측, 2020-2023년, 2023-2024년, 2025년
• 병원
• 클리닉
• 연구기관
• 기타

제7장 지역 및 국가별 분석

• 세계의 COVID 19 최신 치료제 시장, 지역별, 실적과 예측, 2020-2023년, 2023-2024년, 2025년
• 세계의 COVID 19 최신 치료제 시장, 국가별, 실적과 예측, 2020-2023년, 2023-2024년, 2025년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• COVID 19 최신 치료제 시장 경쟁 구도
• COVID 19 최신 치료제 시장 기업 개요
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • Ipca Laboratories Limited
  • Zydus Cadila
  • Regeneron Pharmaceuticals, Inc.

제31장 기타 주요 기업과 혁신 기업

• Sun Pharmaceutical Industries Limited
• AbbVie
• Glenmark Pharmaceuticals Limited
• Eli Lilly and Company
• Wallace Pharmaceuticals, Inc.
• Mylab Discovery Solutions
• Kalbe Farma
• He Qi Group Foundation
• Beijing Jinwofu Bioengineering Technology Company
• Zhejiang Orient Gene Biotech Co. Ltd
• Transasia Bio Medicals
• Vanguard Diagnostics
• HLL Lifecare Limited
• Voxtur Bio Ltd
• Biocryst Pharma

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재성 분석

제36장 부록

LSH

영문 목차

영문목차

The current therapy for COVID-19 pertains to drugs formulated and utilized for treating mild to moderate cases in individuals at higher risk of severe illness from the virus.

Key drug categories in COVID-19 therapy comprise antivirals, monoclonal antibodies, corticosteroids, supplements, antimalarials, interferons, interleukin inhibitors, other anti-infective medications, and similar treatments. Antivirals are specific medications or compounds crafted to impede virus growth and replication, targeting various stages of the viral life cycle or disrupting viral processes. These drugs are administered via oral or intravenous routes and find application across hospitals, clinics, research institutes, and related sectors.

The COVID-19 current therapy market research report is one of a series of new reports from The Business Research Company that provides COVID-19 current therapy market statistics, including COVID-19 current therapy industry global market size, regional shares, competitors with a COVID-19 current therapy market share, detailed COVID-19 current therapy market segments, COVID-19 current therapy market trends and opportunities, and any further data you may need to thrive in the COVID-19 current therapy industry. This COVID-19 current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The COVID-19 current therapy market size has declined steeply in recent years. It will decline from $11.73 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of -50.0%. The decline in the historic period can be attributed to limited treatment options, varying treatment efficacy, supply chain disruptions, rapidly evolving scientific knowledge, emergence of variants.

The COVID-19 current therapy market size is expected to see steep decline in the next few years. It will decline to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of -60.1%. The decline in the forecast period can be attributed to global vaccine rollout impact, long-term effects and chronic cases, regulatory and market access challenges, global economic factors. Major trends in the forecast period include investing in developing monoclonal antibody therapies, convalescent plasma therapies, cell-based therapies, and antiviral therapies, collaboration with government institutions and undergoing strategic partnerships with other pharmaceutical companies.

The outbreak of the COVID-19 pandemic has significantly contributed to the growth of the COVID-19 current therapy market. The World Health Organization (WHO) declared the outbreak a global pandemic, and as of August 2022, reported global COVID-19 cases had reached 581.8 million. With no officially approved drug for COVID-19, there has been a substantial demand for repurposed drugs used in corona therapy. Countries worldwide are grappling with drug shortages, prompting manufacturers to scale up production to meet the surging global demand. The COVID-19 Treatment Acceleration Program (CTAP), initiated by the FDA, is a special emergency program designed to expedite the development of potential COVID-19 therapies for swift availability to patients.

The anticipated growth of the COVID-19 current therapy market is also driven by the expansion of healthcare infrastructure. The healthcare industry plays a crucial role in integrating sectors that provide products and services for curing, preventing, rehabilitating, and offering palliative care to patients. A robust healthcare infrastructure is essential for the effective implementation of COVID-19 therapies, ensuring timely patient care, supporting research and clinical trials, and providing essential resources for optimal treatment delivery. As an illustration, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the US from 6,093 in 2022 to 6,129. Additionally, a report by the UK's Office for National Statistics revealed a 9.4% increase in healthcare spending in the UK between 2020 and 2021 in nominal terms, and a 9.7% increase in real terms. Hence, the expansion of the healthcare industry is a key driver propelling the growth of the COVID-19 current therapy market.

Convalescent Plasma Therapy has emerged as an experimental treatment for COVID-19 patients, involving the use of blood plasma from individuals who have recovered from the disease, known as convalescent plasma (CP). CP therapy is a passive antibody therapy where the isolated plasma, containing antibodies from recovered patients, is administered to individuals with severe disease to suppress virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients contains antibodies that can combat the infection. The FDA recommends CP Therapy as an investigational product during public health emergencies. Approximately 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, with around 7,774 patients enrolled, and 3,809 of them undergoing convalescent plasma transfusion. The experimental nature of convalescent plasma therapy continues to attract attention, with its potential effectiveness depending on sufficient supporting data.

Major companies are intensifying their focus on introducing innovative products to gain a competitive edge. One such innovation is the development of COVID-19 oral antiviral treatments. Antiviral treatments are designed to inhibit the replication and spread of viruses within the body. For example, in November 2021, Pfizer Inc., a US-based pharmaceutical company, launched PAXLOVID, a novel oral antiviral candidate for COVID-19. The Phase 2/3 EPIC-HR study assessing PAXLOVID's efficacy demonstrated a consistent safety profile, making it suitable for patients treated within three days of symptom onset. Interim analysis indicates that PAXLOVID has the potential to save lives, reduce the severity of COVID-19 infections, and prevent up to nine out of ten hospitalizations.

In October 2021, Sanofi and Regeneron Pharmaceuticals announced plans to commence clinical trials using the rheumatoid arthritis medication Kevzara (sarilumab) for managing COVID-19 symptoms. The US Food and Drug Administration (FDA) granted approval for Kevzara's use in treating rheumatoid arthritis. This drug is part of an ongoing collaborative effort between Sanofi and Regeneron focused on antibodies. Kevzara, a fully human monoclonal antibody, functions by obstructing the interleukin-6 (IL-6) pathway through binding and inhibiting the IL-6 receptor. IL-6 potentially contributes to the exacerbated inflammatory response observed in the lungs of severely or critically ill COVID-19 patients. Following a comprehensive evaluation by the Independent Data Monitoring Committee (IDMC) of available Phase 2 and Phase 3 data, adjustments to the trial will prioritize enrolling only critical patients to receive Kevzara at a dosage of 400 mg.

Major companies operating in the COVID-19 current therapy market report are Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals, Inc., Mylab Discovery Solutions, Kalbe Farma, He Qi Group Foundation, Beijing Jinwofu Bioengineering Technology Company, Zhejiang Orient Gene Biotech Co. Ltd., Transasia Bio Medicals, Vanguard Diagnostics, HLL Lifecare Limited, Voxtur Bio Ltd., Biocryst Pharma, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., LAB-CARE Diagnostics, ImmunoScience, CPC Diagnostics, Sysmex Corporation, Atomo Diagnostics, Cellmid Limited, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Hunan Lituo Biotechnology, Hangzhou Biotest Biotech, AmonMed Biotechnology, Getein Biotech, Beijing Tigsun Diagnostics, Vivacheck Lab, Seegene, SD Biosensor, Fujirebio, Siemens Healthcare Pte. Ltd., Senova, LetsGetChecked, Omega Diagnostics, Abingdon Health, Babylon, Motologic, F. Hoffmann-La Roche Ltd., Novacyt Group, AstraZeneca, Pfizer, Zentiva, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Amgen and AdaptiveBiotechnologies, BioNtech, Cytodyn, Heat biologics, Johnson&Johnson, Takeda pharmaceuticals, Vaxart, Vir Biotechnology, Victory Square Health, Abbott Molecular Inc., ACRO Biotech, Advagen Biotech Ltd., BD, Boditech Med, Inc., Cellex Inc., CerTest Biotec, S.L., Hi Technologies, BATM, BioMedomics Quant Lease, CapeBio, Astel Diagnostics, Canary Health Technologies, Thermo Fisher Scientific

North America is the largest region in the COVID-19 current therapy market in 2023. Middle East is expected to be the fastest growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the COVID-19 current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the COVID-19 current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The COVID-19 current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

COVID-19 Current Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on covid-19 current therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for covid-19 current therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The covid-19 current therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Type: Antiviral; Monoclonal Antibodies; Corticosteroid; Supplements; Antimalarial; Interferons And Interleukin Inhibitors; Other Anti-Infective Drugs; Others
• 1) By Route Of Administration: Oral; Intravenous
• 2) By End-User: Hospitals; Clinics; Home Care; Others
• Companies Mentioned: Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Ipca Laboratories Limited; Zydus Cadila; Regeneron Pharmaceuticals, Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. COVID-19 Current Therapy Market Characteristics

3. COVID-19 Current Therapy Market Trends And Strategies

4. COVID-19 Current Therapy Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global COVID-19 Current Therapy Market Size and Growth

• 5.1. Global COVID-19 Current Therapy Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global COVID-19 Current Therapy Historic Market Size and Growth, 2020 - 2023, Value ($ Billion)
• 5.3. Global COVID-19 Current Therapy Forecast Market Size and Growth, 2023 - 2024, 2025F, Value ($ Billion)

6. COVID-19 Current Therapy Market Segmentation

• 6.1. Global COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• Remdesivir
• Hydroxychloroquine
• Ritonavir
• Lopinavir
• Interferon Beta
• Other Drug Type
• 6.2. Global COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• Oral
• Intravenous
• 6.3. Global COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• Hospitals
• Clinics
• Research Institutes
• Other End Users

7. COVID-19 Current Therapy Market Regional And Country Analysis

• 7.1. Global COVID-19 Current Therapy Market, Split By Region, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 7.2. Global COVID-19 Current Therapy Market, Split By Country, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

8. Asia-Pacific COVID-19 Current Therapy Market

• 8.1. Asia-Pacific COVID-19 Current Therapy Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 8.3. Asia-Pacific COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 8.4. Asia-Pacific COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

9. China COVID-19 Current Therapy Market

• 9.1. China COVID-19 Current Therapy Market Overview
• 9.2. China COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion
• 9.3. China COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion
• 9.4. China COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion

10. India COVID-19 Current Therapy Market

• 10.1. India COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 10.2. India COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 10.3. India COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

11. Japan COVID-19 Current Therapy Market

• 11.1. Japan COVID-19 Current Therapy Market Overview
• 11.2. Japan COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 11.3. Japan COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 11.4. Japan COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

12. Australia COVID-19 Current Therapy Market

• 12.1. Australia COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 12.2. Australia COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 12.3. Australia COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

13. Indonesia COVID-19 Current Therapy Market

• 13.1. Indonesia COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 13.2. Indonesia COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 13.3. Indonesia COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

14. South Korea COVID-19 Current Therapy Market

• 14.1. South Korea COVID-19 Current Therapy Market Overview
• 14.2. South Korea COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 14.3. South Korea COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 14.4. South Korea COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

15. Western Europe COVID-19 Current Therapy Market

• 15.1. Western Europe COVID-19 Current Therapy Market Overview
• 15.2. Western Europe COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 15.3. Western Europe COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 15.4. Western Europe COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

16. UK COVID-19 Current Therapy Market

• 16.1. UK COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 16.2. UK COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 16.3. UK COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

17. Germany COVID-19 Current Therapy Market

• 17.1. Germany COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 17.2. Germany COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 17.3. Germany COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

18. France COVID-19 Current Therapy Market

• 18.1. France COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 18.2. France COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 18.3. France COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

19. Italy COVID-19 Current Therapy Market

• 19.1. Italy COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 19.2. Italy COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 19.3. Italy COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

20. Spain COVID-19 Current Therapy Market

• 20.1. Spain COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 20.2. Spain COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 20.3. Spain COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

21. Eastern Europe COVID-19 Current Therapy Market

• 21.1. Eastern Europe COVID-19 Current Therapy Market Overview
• 21.2. Eastern Europe COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 21.3. Eastern Europe COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 21.4. Eastern Europe COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

22. Russia COVID-19 Current Therapy Market

• 22.1. Russia COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 22.2. Russia COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 22.3. Russia COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

23. North America COVID-19 Current Therapy Market

• 23.1. North America COVID-19 Current Therapy Market Overview
• 23.2. North America COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 23.3. North America COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 23.4. North America COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

24. USA COVID-19 Current Therapy Market

• 24.1. USA COVID-19 Current Therapy Market Overview
• 24.2. USA COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 24.3. USA COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 24.4. USA COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

25. Canada COVID-19 Current Therapy Market

• 25.1. Canada COVID-19 Current Therapy Market Overview
• 25.2. Canada COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 25.3. Canada COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 25.4. Canada COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

26. South America COVID-19 Current Therapy Market

• 26.1. South America COVID-19 Current Therapy Market Overview
• 26.2. South America COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 26.3. South America COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 26.4. South America COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

27. Brazil COVID-19 Current Therapy Market

• 27.1. Brazil COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 27.2. Brazil COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 27.3. Brazil COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

28. Middle East COVID-19 Current Therapy Market

• 28.1. Middle East COVID-19 Current Therapy Market Overview
• 28.2. Middle East COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 28.3. Middle East COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 28.4. Middle East COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

29. Africa COVID-19 Current Therapy Market

• 29.1. Africa COVID-19 Current Therapy Market Overview
• 29.2. Africa COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 29.3. Africa COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
• 29.4. Africa COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

30. COVID-19 Current Therapy Market Competitive Landscape And Company Profiles

• 30.1. COVID-19 Current Therapy Market Competitive Landscape
• 30.2. COVID-19 Current Therapy Market Company Profiles
  • 30.2.1. Gilead Sciences, Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Ipca Laboratories Limited
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Zydus Cadila
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Regeneron Pharmaceuticals, Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. COVID-19 Current Therapy Market Other Major And Innovative Companies

• 31.1. Sun Pharmaceutical Industries Limited
• 31.2. AbbVie
• 31.3. Glenmark Pharmaceuticals Limited
• 31.4. Eli Lilly and Company
• 31.5. Wallace Pharmaceuticals, Inc.
• 31.6. Mylab Discovery Solutions
• 31.7. Kalbe Farma
• 31.8. He Qi Group Foundation
• 31.9. Beijing Jinwofu Bioengineering Technology Company
• 31.10. Zhejiang Orient Gene Biotech Co. Ltd
• 31.11. Transasia Bio Medicals
• 31.12. Vanguard Diagnostics
• 31.13. HLL Lifecare Limited
• 31.14. Voxtur Bio Ltd
• 31.15. Biocryst Pharma

32. Global COVID-19 Current Therapy Market Competitive Benchmarking

33. Global COVID-19 Current Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The COVID-19 Current Therapy Market

35. COVID-19 Current Therapy Market Future Outlook and Potential Analysis

• 35.1 COVID-19 Current Therapy Market In 2024 - Countries Offering Most New Opportunities
• 35.2 COVID-19 Current Therapy Market In 2024 - Segments Offering Most New Opportunities
• 35.3 COVID-19 Current Therapy Market In 2024 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료